DAPA-HF One Year on: What Have You Missed?
Published: 31 July 2020
-
Views:
48 -
Likes:
7
-
Views:
48 -
Likes:
7
Overview
This session was part of the 1st e-SPACE Heart Failure Meeting held virtually on July 11-14th 2020 and focused upon analysing the DAPA-HF SGLT2 randomised clinical trial and subsequent sub-analysis data that been published over the last 12 months.
Agenda
- Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF - John McMurray (University of Glasgow, Glasgow, UK)
- Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF - Piotr Ponikowski (Wroclaw Medical University, Wroclaw, PL)
- DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF- Scott Solomon (Brigham & Women’s Hospital, Boston, US)
- Impact of Dapagliflozin Treatment on KCCQ - Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US)
- Dapagliflozin and Diuretic Use in Patients With HFrEF - Alice Jackson (University of Glasgow, Glasgow, UK)
More from this programme
Part 1
Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF
Part 2
Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF
Part 3
DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF
Part 4
Impact of Dapagliflozin Treatment on KCCQ
Part 5
Dapagliflozin and Diuretic Use in Patients With HFrEF
Faculty Biographies
John JV McMurray
Professor of Cardiology
Dr McMurray is Professor of Medical Cardiology and Deputy Director (Clinical) of the Institute of Cardiovascular and Medical Sciences and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.